// App-Quantinova.ai

TPS4699 : Prospect: A randomized, double-blind, phase III efficacy trial of PROSTVAC.

Researchers

Presenter

  • O. Bandman

Principal Investigators

  • A. Delcayre

  • R. Laus

  • W. R. Godfrey

  • P. W. Kantoff

  • J. Schlom

  • J. L. Gulley

Medical Centers

  • National Cancer Institute, Bethesda, MD

  • Radiation Oncology Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Solid malignancies

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Granulocyte-macrophage-colony stimulating factor

Drug/Treatment

  • Androgen Tear

  • GM-CSF

Outcome

  • N/A

Study Design

  • randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved